|
Univariate analysis of MACE in the subgroups of the study population |
|||
| MACE |
|||
|
|
|||
| Subgroups |
n |
Survival (%) |
p |
|
|
|||
| Demographic characteristics |
|||
| Males/Females |
779/184 |
78.8/80.6 |
0.631 |
| Age ≥ 65/< 65 years |
516/447 |
79.4/78.6 |
0.622 |
| Medical history |
|||
| Hypertension yes/no |
405/558 |
77.1/80.2 |
0.852 |
| Diabetes mellitus yes/no |
123/840 |
73.7/79.9 |
0.481 |
| Hypercholesterolemia yes/no |
465/498 |
83.0/76.0 |
0.124 |
| Past or current smokers yes/no |
491/472 |
76.5/81.9 |
0.380 |
| BMI ≥ 25/< 25 (kg/m2) |
619/344 |
79.1/78.7 |
0.253 |
| Family history of MI yes/no |
272/691 |
78.5/79.4 |
0.401 |
| Prior MI yes/no |
297/666 |
82.0/77.9 |
0.292 |
| Prior PCI yes/no |
128/835 |
76.3/79.6 |
0.988 |
| Prior CABG yes/no |
89/874 |
71.3/79.9 |
0.564 |
| GP III a polymorphism |
|||
| A1A1/A1A2/A2A2 |
690/248/25 |
78.3/80.6/91.7 |
0.777 |
| Coronary artery vessels diseased |
|||
| Single+two-/three-vessel disease |
746/217 |
80.2/75.3 |
0.109 |
| LVEF ≥ 40%/< 40% |
808/155 |
80.4/73.5 |
0.012 |
| Therapy |
|||
| ACE inhibitor yes/no |
316/647 |
69.2/81.9 |
0.062 |
| Beta-blocker yes/no |
546/417 |
74.9/81.3 |
0.262 |
| Statin yes/no |
334/629 |
76.5/79.2 |
0.770 |
| Therapy during follow-up |
|||
| Statin yes/no |
462/501 |
82.6/76.2 |
0.031 |
| ACE inhibitor yes/no |
338/625 |
89.3/73.3 |
< 0.001 |
| Beta-blocker yes/no |
580/383 |
86.5/69.3 |
< 0.001 |
|
ACE, angiotensin converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention. | |||
Le Hello et al. Thrombosis Journal 2007 5:19 doi:10.1186/1477-9560-5-19 |
|||